Skip to main content

Table 2 Hematological parameters of LA-SCCHN patients in both the groups

From: Comparative study on hemato- and nephrotoxicity profile of weekly versus every 3-weekly cisplatin dosage during induction chemotherapy in locally advanced head neck squamous cell carcinoma

Hematological parameters

Weekly dose cisplatin (mean dose: 30 mg/m2) (n = 15)

Every 3-week dose cisplatin (mean dose: 100 mg/m2) (n = 15)

Control

ANOVA

(p value)

Pre chemotherapy

Post chemotherapy

Change (%)

Pre chemotherapy

Post chemotherapy

Change (%)

WBC count

8.6 ± 2.5 a

6.3 ± 1.6 a

− 26.6

6.8 ± 1.9

5.7 ± 1.1

− 16.5

5.5 ± 1.6

***

Neutrophil count

5.8 ± 2.4a2

3.5 ± 1.9a2

− 40.2

4.3 ± 1.9

3.48 ± 1.3

− 19.6

3.4 ± 1.2

** (.0018)

Lymphocyte count

2.2 ± 1.1

1.7 ± 0.7

− 21.4

1.5 ± 0.6b

1.2 ± 0.6b

− 23.3

1.8 ± 0.6

* (0.0115)

RBC count

4.8 ± 0.8 a1

3.91 ± 0.5a1

− 17.9

4.5 ± 0.8

3.9 ± 0.5

− 12.1

4.4 ± 0.5x

** (.0017)

Platelet count

222.6 ± 44.4y

166 ± 44.2y,x

− 25.4

159. ± 24.1

136.1 ± 12.4z

− 14.8

222.6 ± 44.4x,z

***

  1. ***p < .001 (extremely significant)
  2. **p < .01(very significant)
  3. *p < .05(significant)
  4. On comparing the different groups by Tukey-Kramer multiple comparisons test, the corresponding letters indicate the significance level between groups as follows:
  5. a, a1, a2P < .01(very significant)
  6. b,x,y,zp < .001(extremely significant). Changes in terms of decrease in levels are indicated in minus sign. RBC red blood corpuscles, WBC white blood cells